Expression of activation markers on decidual and peripheral blood CD4+ T cells, CD8+ T cells, and CD16−CD56bright NK cells
Decidua | Peripheral blood | |
---|---|---|
% of positive cells (mean ± SD) | % of positive cells (mean ± SD) | |
CD4+ T cells | ||
IL-2Rα (CD25) | 26.9 ± 5.0 | 20.5 ± 5.2 |
IL-2Rβ (CD122) | 8.6 ± 4.6 | 1.5 ± 0.5 |
CD69 | 58.3 ± 12.7 | 0.9 ± 0.5 |
HLA-DR | 67.7 ± 14.8 | 11.8 ± 4.7 |
CD8+ T cells | ||
IL-2Rα (CD25) | 6.2 ± 2.9 | 2.5 ± 1.5 |
IL-2Rβ (CD122) | 17.7 ± 7.2 | 10.6 ± 3.4 |
CD69 | 73.3 ± 14.3 | 3.5 ± 0.7 |
HLA-DR | 82.9 ± 13.5 | 20.6 ± 7.4 |
CD16−CD56bright NK cells | ||
CD69 | 58.4 ± 11.3 | 0.07 ± 0.03 |
HLA-DR | 11.3 ± 4.5 | 0.7 ± 0.2 |
SD: standard deviation
Note. Adapted from “Accumulation of CD16−CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.” by Nishikawa K, Saito S, Morii T, Hamada K, Ako H, Narita N, et al. Int Immunol. 1991;3:743–50 (https://academic.oup.com/intimm/article-lookup/doi/10.1093/intimm/3.8.743). © 1991 Oxford University Press;
“Expression of activation antigens CD69, HLA-DR, interleukin-2 receptor-alpha (IL-2Rα) and IL-2Rβ on T cells of human decidua at an early stage of pregnancy.” by Saito S, Nishikawa K, Morii T, Narita N, Enomoto M, Ichijo M. Immunology. 1992;75:710–2 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1384855). © 1992 Wiley Online Library.
SS wrote the paper, and AN consulted on the content of the paper. TS did research on Treg and consulted on the content of the paper. ST submitted materials for the paper.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This study was supported by Japan Agency for Medical Research and Development (grant JP18gk0110018 and JP21gk0110047) and Japan Society for the Promotion of Science (KAKENHI grant JP19K09750, 20K09614, 19K18690 and 21K16764). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2021.